Copyright West LLC. Minimum 15 minutes delayed.

Investors & Media

Press Release

Dicerna™ Appoints Rob Ciappenelli Chief Commercial Officer

Jun 4, 2019

— Company Expands Management Team and Bolsters Commercial Capabilities to Support Continued Growth —

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 4, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Rob Ciappenelli as chief commercial officer of Dicerna and member of the Company’s executive leadership team, effective immediately.

“Rob is a proven global business executive with deep and diverse experience leading commercial operations in our industry,” said Douglas M. Fambrough, Ph.D., president and chief executive officer of Dicerna. “With his track record for building efficient organizations and successfully launching multiple innovative products, Rob is ideally suited to lead our commercial team as we advance our robust pipeline of GalXC™-based therapies, including DCR-PHXC for the treatment of patients with all forms of primary hyperoxaluria and DCR-HBVS for the treatment of adult patients with chronic hepatitis B virus infection. We look forward to working closely with Rob as we pursue our goal of creating next-generation RNAi therapies that reduce disease burden for all patients.”

With more than 28 years of global experience across the pharmaceutical, biotech and healthcare consulting industries, Mr. Ciappenelli brings to Dicerna extensive experience in developing commercial organizations and establishing lean operational infrastructure. Through leadership roles with Momenta Pharmaceuticals, Shire Pharmaceuticals and Sunovion Pharmaceuticals, Mr. Ciappenelli has worked to improve patient care while driving business performance. His expertise spans rare disease, neurological disorders and diseases of the respiratory and gastrointestinal systems.

“I am drawn to Dicerna by its people, its pipeline of next-generation RNAi therapies and the transformative potential of its GalXC technology platform,” said Mr. Ciappenelli. “I am eager to work with the talented team at Dicerna to build and implement the Company’s commercial strategy and fulfill its mission of improving the lives of patients with serious, life-threatening diseases.”

Mr. Ciappenelli joins Dicerna from Momenta Pharmaceuticals, where he was global head of commercial. In that capacity, Mr. Ciappenelli managed a portfolio of 13 programs ranging from early development to partnered in-market products. Prior to Momenta, he held several leadership positions at Shire Pharmaceuticals (now part of Takeda), across commercial operations and business planning including global franchise operations lead for Shire’s Fabry (Replagal®) and Gaucher (Vpriv®) programs. Mr. Ciappenelli’s pharmaceutical commercialization experience also includes various leadership positions at Sunovion Pharmaceuticals, where he served as vice president of commercial operations, executive director of commercial services and sales training and executive director of central nervous system marketing.

Mr. Ciappenelli earned a Bachelor of Business Administration (B.B.A.) in Finance from the University of Massachusetts at Amherst and a Master of Business Administration (M.B.A.) from the Harvard Graduate School of Business Administration.

About Dicerna™ Pharmaceuticals, Inc.

Dicerna™ Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Boehringer Ingelheim, Eli Lilly and Company and Alexion Pharmaceuticals. For more information, please visit

Cautionary Note on Forward-Looking Statements

This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include risks relating to Dicerna’s clinical and preclinical research and other risks identified under the heading "Risk Factors" included in the Company’s most recent Form 10-Q filing and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Dicerna™, GalXC™ and PHYOX™ are trademarks of Dicerna Pharmaceuticals, Inc.

Source: Dicerna™ Pharmaceuticals, Inc.

Stern Investor Relations, Inc.
Kendra Packard, 212-362-1200

Alex Van Rees, 973-442-1555 ext. 111